Rajshree Kandadai joined Acrivon in September 2023 as vice president of business development. Rajshree has over 20 years of experience in business development and licensing, corporate strategy and alliance management roles with a strong track record in both biotech and pharma. Prior to Acrivon, Rajshree led licensing activities for oncology assets at Mass General Brigham (MGB) Innovation for the Brigham and Woman’s Hospital, the Mass General Hospital and the MGH Vaccine and Immunotherapy center and was responsible for driving several high value transactions. Prior to joining MGB, from 2010 to 2019, Rajshree was senior director corporate development and strategy at Aurigene Oncology. During her tenure at Aurigene, Rajshree established over 15 collaborations, including with big pharma and biotech companies across the U.S., Europe and Japan, delivering over $250 million in realized revenues. Previously, she served as a healthcare equity research analyst both at UBS ISC, where she led the healthcare equity research team, and at HSBC where she covered the U.S. healthcare sector. She holds an Master’s degree in hospital management and a B.S. in microbiology.